Prevalence of extended spectrum β-lactamase and ampc β-lactamase producing bacteria in urinary tract infection patients in Bangladesh

Mitu, F. S.; Al-Maruf, M. A.; Mahanty, Arpan; ., A.K.M.N. Huda; Khan, Shazia; Rahman, Mostaqimur

doi:10.21161/mjm.180193

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ESBL have been frequently reported on the Asian subcontinent since the late 1990s. In Bangladesh, ESBL have been reported for more than two decades [81]. The globally dominant ESBL blaCTX-M-15 was first reported in India in the mid-1990s and is still a dominant ESBL type in India, Bangladesh, and Pakistan [82].…”

Section: Current Status Of Esbl In South Asian Developing Countriesmentioning

confidence: 99%

Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities

Husna,

Rahman,

Badruzzaman

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The rise of antimicrobial resistance, particularly from extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E), poses a significant global health challenge as it frequently causes the failure of empirical antibiotic therapy, leading to morbidity and mortality. The E. coli- and K. pneumoniae-derived CTX-M genotype is one of the major types of ESBL. Mobile genetic elements (MGEs) are involved in spreading ESBL genes among the bacterial population. Due to the rapidly evolving nature of ESBL-E, there is a lack of specific standard examination methods. Carbapenem has been considered the drug of first choice against ESBL-E. However, carbapenem-sparing strategies and alternative treatment options are needed due to the emergence of carbapenem resistance. In South Asian countries, the irrational use of antibiotics might have played a significant role in aggravating the problem of ESBL-induced AMR. Superbugs showing resistance to last-resort antibiotics carbapenem and colistin have been reported in South Asian regions, indicating a future bleak picture if no urgent action is taken. To counteract the crisis, we need rapid diagnostic tools along with efficient treatment options. Detailed studies on ESBL and the implementation of the One Health approach including systematic surveillance across the public and animal health sectors are strongly recommended. This review provides an overview of the background, associated risk factors, transmission, and therapy of ESBL with a focus on the current situation and future threat in the developing countries of the South Asian region and beyond.

show abstract

Section: Current Status Of Esbl In South Asian Developing Countriesmentioning

confidence: 99%